FDA's abrupt flip-flop on Moderna's mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of criticism from public health experts.

Continue Reading

News Source: medicalxpress.com